SCHEMBL2464428

SCHEMBL2464428

CCOC(=O)c1cc(N)ccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 0.73
L3MBTL1 Q9Y468 1/20 0.73
MEN1 O00255 2/20 0.54
POLB P06746 2/20 0.54
KMT2A Q03164 2/20 0.54
ALPL P05186 1/20 0.54
ALPI P09923 1/20 0.54
ALPG P10696 1/20 0.54
ATM Q13315 2/20 0.52
PLEC Q15149 1/20 0.52
ABCB1 P08183 1/20 0.50
AKR1B1 P15121 1/20 0.50
CFTR P13569 1/20 0.48
PAX8 Q06710 1/20 0.48
GOPC Q9HD26 1/20 0.48
CA9 Q16790 9/20 0.47
CA1 P00915 7/20 0.47
CA2 P00918 7/20 0.47
CA12 O43570 4/20 0.47
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30882008 0.93 USP2 (0.66) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL4631151 0.93 USP2 (0.66) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL15496802 0.89 USP2 (0.77) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL17920161 0.88 USP2 (0.78) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL30023431 0.84 USP2 (1.00) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL3481432 0.84 USP2 (1.00) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL4630894 0.82 USP2 (0.50) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL23084928 0.81 USP2 (0.71) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL14646715 0.81 USP2 (0.61) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL13384808 0.79 USP2 (0.85) USP2L3MBTL1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 US disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 WO disclosed
US-20080275215-A1 Fluorescein-Based Compounds And Their Use For Peptide Synthesis COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2008-11-06 US disclosed
EP-1749870-B1 Fluorescein-based compounds and their use for peptide synthesis COMMISSARIAT ENERGIE ATOMIQUE (FR) 2008-05-14 EP disclosed
EP-1749870-A1 Fluorescein-based compounds and their use for peptide synthesis COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2007-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275215-A1 Fluorescein-Based Compounds And Their Use For Peptide Synthesis DNPEP, ANPEP, PEPD USP2 1795/4885L3MBTL1 3821/4885MEN1 2416/4885
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 USP2 3599/4885L3MBTL1 528/4885MEN1 4495/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 USP2 3599/4885L3MBTL1 528/4885MEN1 4495/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 USP2 3599/4885L3MBTL1 528/4885MEN1 4495/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 USP2 3599/4885L3MBTL1 528/4885MEN1 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.